TNG908

Item no.	HY-148419-100mg
Manufacturer	MedChem Express
CASRN	2760481-53-4
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	98.94
Citations	[1]K. Briggs, et al. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer.MOLECULAR TARGETED AGENTS 2 VOLUME 174, SUPPLEMENT 1, S84, OCTOBER 2022.
Smiles	CC1=CC(NC(C(N2[C@@H](C3=CC=C(SC=N4)C4=C3)CC[C@@H](C2)C)=O)=O)=CN=C1N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Histone Methyltransferase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	409.50
Product Description	TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics
Isoform	PRMT5
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-148419-100mg-safety-datasheet.pdf